# Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine

> **NCT06263387** · — · RECRUITING · sponsor: **French Innovative Leukemia Organisation** · enrollment: 230 (estimated)

## Conditions studied

- AML, Adult

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06263387
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-04
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-30
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06263387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06263387, "Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06263387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*